Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer

Despite recent advances in the treatment of non-small cell lung cancer (NSCLC), less than 10% of patients survive the first five years when the disease has already spread at primary diagnosis. Methods: Blood samples were taken from 118 NSCLC patients at primary diagnosis or at progression of the dis...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eva Obermayr, Nina Koppensteiner, Nicole Heinzl, Eva Schuster, Barbara Holzer, Hannah Fabikan, Christoph Weinlinger, Oliver Illini, Maximilian Hochmair, Robert Zeillinger
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	non-small cell lung cancer circulating tumor cells cancer stem cell microfluidics gene expression analysis Medicine R
Acceso en línea:	https://doaj.org/article/62a59bcbe60c4ca2b50310a47f3a0116
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:62a59bcbe60c4ca2b50310a47f3a0116
record_format	dspace
spelling	oai:doaj.org-article:62a59bcbe60c4ca2b50310a47f3a01162021-11-25T18:08:09ZCancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer10.3390/jpm111112252075-4426https://doaj.org/article/62a59bcbe60c4ca2b50310a47f3a01162021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1225https://doaj.org/toc/2075-4426Despite recent advances in the treatment of non-small cell lung cancer (NSCLC), less than 10% of patients survive the first five years when the disease has already spread at primary diagnosis. Methods: Blood samples were taken from 118 NSCLC patients at primary diagnosis or at progression of the disease before the start of a new treatment line and enriched for circulating tumor cells (CTCs) by microfluidic Parsortix™ (Angle plc, Guildford GU2 7AF, UK) technology. The gene expression of epithelial cancer stem cell (CSC), epithelial to mesenchymal (EMT), and lung-related markers was assessed by qPCR, and the association of each marker with overall survival (OS) was evaluated using log-rank tests. Results: EpCAM was the most prevalent transcript, with 53.7% positive samples at primary diagnosis and 25.6% at recurrence. EpCAM and CK19, as well as NANOG, PROM1, TERT, CDH5, FAM83A, and PTHLH transcripts, were associated with worse OS. However, only the CSC-specific NANOG and PROM1 were related to the outcome both at primary diagnosis (NANOG: HR 3.21, 95%CI 1.02–10.14, <i>p</i> = 0.016; PROM1: HR 4.23, 95% CI 0.65–27.56, <i>p</i> = 0.007) and disease progression (NANOG: HR 4.17, 95%CI 0.72–24.14, <i>p</i> = 0.025; PROM1: HR 4.77, 95% CI 0.29–78.94, <i>p</i> = 0.032). Conclusions: The present study further underlines the relevance of the molecular characterization of CTCs. Our multi-marker analysis highlighted the prognostic value of cancer stem cell-related transcripts at primary diagnosis and disease progression.Eva ObermayrNina KoppensteinerNicole HeinzlEva SchusterBarbara HolzerHannah FabikanChristoph WeinlingerOliver IlliniMaximilian HochmairRobert ZeillingerMDPI AGarticlenon-small cell lung cancercirculating tumor cellscancer stem cellmicrofluidicsgene expression analysisMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1225, p 1225 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-small cell lung cancer circulating tumor cells cancer stem cell microfluidics gene expression analysis Medicine R
spellingShingle	non-small cell lung cancer circulating tumor cells cancer stem cell microfluidics gene expression analysis Medicine R Eva Obermayr Nina Koppensteiner Nicole Heinzl Eva Schuster Barbara Holzer Hannah Fabikan Christoph Weinlinger Oliver Illini Maximilian Hochmair Robert Zeillinger Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
description	Despite recent advances in the treatment of non-small cell lung cancer (NSCLC), less than 10% of patients survive the first five years when the disease has already spread at primary diagnosis. Methods: Blood samples were taken from 118 NSCLC patients at primary diagnosis or at progression of the disease before the start of a new treatment line and enriched for circulating tumor cells (CTCs) by microfluidic Parsortix™ (Angle plc, Guildford GU2 7AF, UK) technology. The gene expression of epithelial cancer stem cell (CSC), epithelial to mesenchymal (EMT), and lung-related markers was assessed by qPCR, and the association of each marker with overall survival (OS) was evaluated using log-rank tests. Results: EpCAM was the most prevalent transcript, with 53.7% positive samples at primary diagnosis and 25.6% at recurrence. EpCAM and CK19, as well as NANOG, PROM1, TERT, CDH5, FAM83A, and PTHLH transcripts, were associated with worse OS. However, only the CSC-specific NANOG and PROM1 were related to the outcome both at primary diagnosis (NANOG: HR 3.21, 95%CI 1.02–10.14, <i>p</i> = 0.016; PROM1: HR 4.23, 95% CI 0.65–27.56, <i>p</i> = 0.007) and disease progression (NANOG: HR 4.17, 95%CI 0.72–24.14, <i>p</i> = 0.025; PROM1: HR 4.77, 95% CI 0.29–78.94, <i>p</i> = 0.032). Conclusions: The present study further underlines the relevance of the molecular characterization of CTCs. Our multi-marker analysis highlighted the prognostic value of cancer stem cell-related transcripts at primary diagnosis and disease progression.
format	article
author	Eva Obermayr Nina Koppensteiner Nicole Heinzl Eva Schuster Barbara Holzer Hannah Fabikan Christoph Weinlinger Oliver Illini Maximilian Hochmair Robert Zeillinger
author_facet	Eva Obermayr Nina Koppensteiner Nicole Heinzl Eva Schuster Barbara Holzer Hannah Fabikan Christoph Weinlinger Oliver Illini Maximilian Hochmair Robert Zeillinger
author_sort	Eva Obermayr
title	Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
title_short	Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
title_full	Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
title_fullStr	Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
title_full_unstemmed	Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
title_sort	cancer stem cell-like circulating tumor cells are prognostic in non-small cell lung cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/62a59bcbe60c4ca2b50310a47f3a0116
work_keys_str_mv	AT evaobermayr cancerstemcelllikecirculatingtumorcellsareprognosticinnonsmallcelllungcancer AT ninakoppensteiner cancerstemcelllikecirculatingtumorcellsareprognosticinnonsmallcelllungcancer AT nicoleheinzl cancerstemcelllikecirculatingtumorcellsareprognosticinnonsmallcelllungcancer AT evaschuster cancerstemcelllikecirculatingtumorcellsareprognosticinnonsmallcelllungcancer AT barbaraholzer cancerstemcelllikecirculatingtumorcellsareprognosticinnonsmallcelllungcancer AT hannahfabikan cancerstemcelllikecirculatingtumorcellsareprognosticinnonsmallcelllungcancer AT christophweinlinger cancerstemcelllikecirculatingtumorcellsareprognosticinnonsmallcelllungcancer AT oliverillini cancerstemcelllikecirculatingtumorcellsareprognosticinnonsmallcelllungcancer AT maximilianhochmair cancerstemcelllikecirculatingtumorcellsareprognosticinnonsmallcelllungcancer AT robertzeillinger cancerstemcelllikecirculatingtumorcellsareprognosticinnonsmallcelllungcancer
_version_	1718411562122739712

Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer

Ejemplares similares